NCT06682806Phase 2Terminated

A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

Study sponsor: Prelude Therapeutics Incorporated

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-01-23Actual

Enrollment · participants6Actual

Source updated2026-02-02Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-02-02 · 4 fields changed

Actual enrollment decreased by 1 participants

− Before

~~7 participants (actual)~~

+ After

6 participants (actual)

Completion date type changed

− Before

~~Estimated~~

+ After

Actual

Primary completion date changed

− Before

~~Aug 2027~~

+ After

23 Jan 2026

Recruitment status changed

− Before

~~Active not recruiting~~

+ After

Terminated

Check registry source

Study details

Conditions studied

Advanced Solid Tumor; Esophageal Cancer; Metastatic Solid Tumor; Non-small Cell Lung Cancers; SMARCA4 Gene Mutation

Treatments or interventions studied

PRT3789Drug
pembrolizumabDrugAlso known as KEYTRUDA®

Primary outcomes · main study measures

Read the study measures

measure: Safety and tolerability of PRT3789 in combination with pembrolizumab as measured by incidence of DLTs (Part 1); description: Safety and tolerability will be evaluated by incidence of dose-limiting toxicities (DLTs); timeFrame: Baseline through completion of study, an average of 2 years; measure: Safety and tolerability of PRT3789 in combination with pembrolizumab as measured by incidence and severity of AEs according to NCI CTCAE (Part 1); description: Safety and tolerability will be evaluated by incidence and severity of adverse events (AEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE); timeFrame: Baseline through study completion, an average of 2 years; measure: Efficacy of PRT3789 in combination with pembrolizumab in patients with advanced or metastatic esophageal or NSCLC and deleterious SMARCA4 mutation: Objective Response Rate (Part 2); description: Objective response rate defined as the proportion of patients with a confirmed best overall response of either complete response or partial response, as determined per investigator assessment by RECIST v1.1; timeFrame: Baseline through study completion, an average of 2 years; measure: Efficacy of PRT3789 in combination with pembrolizumab in patients with advanced or metastatic esophageal or NSCLC and deleterious SMARCA4 mutation: Duration of Response (Part 2); description: Duration of response defined as the time from the date of the first documented response (complete response or partial response) to the earliest date of disease progression, as determined per investigator assessment by RECIST v1.1, or death due to any cause; timeFrame: Baseline through study completion, an average of 2 years

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history